Fig 1: Expression of galectin-9 in CC tissue. CC specimen with high expression (A) 10X amplification, (B) 20X amplification. CC tissue with low galectin-9 expression (C) 10X amplification and (D) 20X amplification.
Fig 2: ATXN3 promotes Galectin-9 expression in human colon cancer cells.A, ATXN3 targeted deletion in different colon cancer cells were generated. The protein levels of ATXN3(top panel), Galectin-9 (middle panel), and loading control β-actin were determined by western blotting. B, the levels of Galectin-9 in (A) and repeated experiments were quantified using Image J software. C and D, representative flow cytometry plots and quantification by MFI of Galectin-9 in HCT116, MC38, and CT26 cells. E, ATXN3 and Galectin-9 mRNA levels were analyzed by reverse transcription quantitative PCR (RT -qPCR) in HCT116 cells. F, ATXN3 and Galectin-9 mRNA levels were analyzed by reverse transcription quantitative PCR (RT -qPCR) in MC38 cells. G, ATXN3 and Galectin-9 mRNA levels were analyzed by reverse transcription quantitative PCR (RT -qPCR) in CT26 cells. B, D, E, F and G: 2-tailed unpaired t test; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Fig 3: Tim-3 and galectin-9 were repressed by DNMT3A mediated DNA methylation. a Western blotting analysis of SiHa and HeLa cells knocked-down DNMT3A against Tim-3, galectin-9 and DNMT3A. b Detection of the expression of DNMT3A and Tim-3, galectin-9 in DNMT3A specific siRNA transfected overexpressed SUV39H1 SiHa and HeLa cells by western blotting. c The methylation level of HAVCR2 and LGALS9 promoter regions were monitored by MS-PCR in DNMT3A knockdown SiHa and HeLa cells. d Methylated and unmethylated levels were quantified as M/M + U% and U/M + U%, respectively. e, g Schematic representation of the four regions of the HAVCR2 and LGALS9 promoter regions amplified in the chromatin immunoprecipitation (ChIP)‑quantitative PCR (qPCR) experiment. f, h Chromatin was cross-linked, fragmented and immunoprecipitated with either IgG (mock) or anti-DNMT3A ChIP-grade antibody and the purified DNA was used to amplify with respective primer pairs for indicated four regions in the HAVCR2 and LGALS9 promoter regions in qPCR. The enrichment of DNMT3A on HAVCR2 and LGALS9 promoter regions relative to IgG in SiHa and HeLa cells, and H3 against RPL30 was used as positive control. *P < 0.05, **P < 0.01
Fig 4: Statistical analysis of IHC scores for TIM-3+ (a) and Gal-9+ (b) TIL distribution in different risk of GIST patients, P = 0.001 and P < 0.001, respectively.
Fig 5: Representative images of individual expression levels of TIM-3 and Gal-9 are shown with their corresponding frequencies in GIST cohorts. The symbol in the top indicates the intensity scores of indicated immune markers. The number in the bottom of every picture indicates the corresponding amounts of the score (original magnification: ×200; Scale bars, 200 μm).
Supplier Page from Abcam for Anti-galectin 9/Gal-9 antibody